Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Bibliographic Details

Published in:	Cancer Cell 2022-06, Vol.40 (6), p.590-591
Main Authors:	Stuver, Robert, Shah, Gunjan L., Korde, Neha S., Roeker, Lindsey E., Mato, Anthony R., Batlevi, Connie L., Chung, David J., Doddi, Sital, Falchi, Lorenzo, Gyurkocza, Boglarka, Hamilton, Audrey, Lin, Ya-Hui, Jakubowski, Ann A., Joffe, Erel, Landau, Heather L., Lin, Richard J., Mailankody, Sham, Palomba, M. Lia, Park, Jae H., Perales, Miguel-Angel, Ponce, Doris M., Ramanathan, Lakshmi V., Salles, Gilles A., Scordo, Michael, Seo, Susan K., Shah, Urvi A., Stein, Eytan M., Straus, David, Usmani, Saad Z., Young, James W., Zelenetz, Andrew D., Noy, Ariela, Vardhana, Santosha A.
Format:	Article
Language:	eng
Subjects:	Antibodies, Monoclonal Antibodies, Neutralizing COVID-19 Drug Treatment Drug Combinations Hematologic Neoplasms - drug therapy Humans Letter SARS-CoV-2
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!